PIPELINE/CONTINUUM VISTA
This is a randomized, double-blind study of PIPE-307 or placebo to see if it can help patients with relapsing-remitting multiple sclerosis.
Inclusion Criteria:
- 18-50 years of age, a diagnosis of relapsing-remitting multiple sclerosis
- Stable immunomodulatory treatment
- Diagnosed within the last 10 years
- Without clinical MS relapse or treatment with corticosteroids within last 6 months
What to Expect
Subjects will be randomized into 1 of 3 separate cohorts (1:1:1 randomization ratio, PIPE-307 Dose A:PIPE-307 Dose B: Placebo). There will be a 28-day screening period followed by a 26-week treatment period. Safety will be assessed by periodic measurements of vital signs (VS), physical (PE) and neurological examinations, electrocardiograms (ECG), blood laboratory analyses and occurrence of adverse events (AE)
For more information click the link below or contact Allison Clarke at aemborsky@dentinstitute.com or 716-558-3543